179 related articles for article (PubMed ID: 30360950)
1. Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan.
Hikino K; Fukunaga K; Mushiroda T
Drug Metab Pharmacokinet; 2018 Dec; 33(6):243-249. PubMed ID: 30360950
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels.
Yoon DY; Lee S; Ban MS; Jang IJ; Lee S
Transl Clin Pharmacol; 2020 Dec; 28(4):189-198. PubMed ID: 33425802
[TBL] [Abstract][Full Text] [Related]
4. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
Pritchard D; Patel JN; Stephens LE; McLeod HL
Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
[TBL] [Abstract][Full Text] [Related]
5. Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels.
Otsubo Y; Asahina Y; Noguchi A; Sato Y; Ando Y; Uyama Y
Drug Metab Pharmacokinet; 2012; 27(1):142-9. PubMed ID: 22201121
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic biomarkers in drug labels: what do they tell us?
Tutton R
Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
[TBL] [Abstract][Full Text] [Related]
7. Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies.
Nagy M; Attya M; Patrinos GP
Pharmacogenomics; 2020 Nov; 21(17):1247-1264. PubMed ID: 33124490
[TBL] [Abstract][Full Text] [Related]
8. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
[TBL] [Abstract][Full Text] [Related]
9. Patients dispensed medications with actionable pharmacogenomic biomarkers: rates and characteristics.
Liu D; Olson KL; Manzi SF; Mandl KD
Genet Med; 2021 Apr; 23(4):782-786. PubMed ID: 33420348
[TBL] [Abstract][Full Text] [Related]
10. Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data.
Kordou Z; Skokou M; Tsermpini EE; Chantratita W; Fukunaga K; Mushiroda T; Patrinos GP; Koromina M
Pharmacol Res; 2021 May; 167():105538. PubMed ID: 33705851
[TBL] [Abstract][Full Text] [Related]
11. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
[TBL] [Abstract][Full Text] [Related]
12. Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.
Selig DJ; Livezey JR; Chin GC; DeLuca JP; Guillory Ii WO; Kress AT; Oliver TO; Por ED
Mil Med; 2021 Dec; 187(Suppl 1):9-17. PubMed ID: 34967405
[TBL] [Abstract][Full Text] [Related]
13. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
Otsubo Y
Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
[TBL] [Abstract][Full Text] [Related]
14. Coverage of pharmacogenetic tests by private health insurance companies.
Park SK; Thigpen J; Lee IJ
J Am Pharm Assoc (2003); 2020; 60(2):352-356.e3. PubMed ID: 31843376
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020).
Kim JA; Ceccarelli R; Lu CY
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33806453
[TBL] [Abstract][Full Text] [Related]
17. Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.
Surh LC; Pacanowski MA; Haga SB; Hobbs S; Lesko LJ; Gottlieb S; Papaluca-Amati M; Patterson SD; Hughes AR; Kim MJ; Close SL; Mosteller M; Zineh I; Dechairo B; Cohen NA
Pharmacogenomics; 2010 Dec; 11(12):1637-47. PubMed ID: 21142906
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.
Shekhani R; Steinacher L; Swen JJ; Ingelman-Sundberg M
Clin Pharmacol Ther; 2020 May; 107(5):1240-1255. PubMed ID: 31715018
[TBL] [Abstract][Full Text] [Related]
19. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
Verbelen M; Weale ME; Lewis CM
Pharmacogenomics J; 2017 Oct; 17(5):395-402. PubMed ID: 28607506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
